An alternate drug screen conducted in an osteosarcoma cell line with a mutant p53 protein, identified a compound named PRIMA-1 that was able to restore DNA binding capability to mutant p53, resulting in apoptosis and tumour suppression when tested in vivo71. Here, TP53 is linked to neoplasm.